Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

Rhea-AI Summary

Monte Rosa Therapeutics (MRTX) will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28, 2023. The company is a clinical-stage biotechnology firm developing novel molecular glue degrader (MGD)-based medicines.

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, November 28, 2023, at 3:30 p.m. ET.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 90 days following the presentation.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk, Kendall IR
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

What is Monte Rosa Therapeutics (MRTX) participating in?

Monte Rosa Therapeutics (MRTX) will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28, 2023.

What type of company is Monte Rosa Therapeutics (MRTX)?

Monte Rosa Therapeutics (MRTX) is a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines.

Where can the webcast of the presentation be accessed?

The webcast of the presentation will be accessible via the 'Events & Presentations' section of Monte Rosa’s website at ir.monterosatx.com.

For how long will the archived version of the presentation be available?

An archived version of the presentation will be made available for 90 days following the event.